Article preview from IN VIVO - April, 2012
Pfizer and Zhejiang Hisun Pharmaceutical together invested $545 million to create a Chinese generics joint venture. Dainippon Sumitomo Pharma expanded its cancer pipeline though the acquisition of Boston Biomedical. Driven by a large amount of FOPOs, biopharma financing totaled $1.8 billion in February, while device companies raised $248 million.
Article preview from IN VIVO - April, 2012
Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries.
- Pfizer and Zhejiang Hisun Pharmaceutical together invested $545 million to create a Chinese joint venture that will manufacture branded generics.
- Dainippon Sumitomo Pharma expanded its cancer pipeline by purchasing partner Boston Biomedical for $200 million up front and up to $2.43 billion in earn-outs.
- Financing from a large amount of FOPOs, including two $100 million-plus offerings from Vivus and Ardea, propelled biopharma funding to $1.8 billion in February, more than double January’s $825 million. Device financing decreased, down 22% to $248 million (vs. January’s $316 million). 2012’s first device IPO occurred in February, EOS Imaging’s $50 million listing on NYSE’s Euronext exchange.
Continued...
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments